X4 Pharmaceuticals to Present at March Investor Conferences

BOSTON, March 03, 2022 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel CXCR4-targeted small molecule therapeutics to benefit patients with diseases of the immune system, today announced that management will participate in a panel at the 42nd Annual Cowen Healthcare Conference on Monday, March 7, 2022 and in a fireside chat at the 32nd Annual Oppenheimer Healthcare Conference on Tuesday, March 15, 2022.

Details are as follows:

Conference: 42nd Annual Cowen Healthcare Conference
Format: Non-Malignant Hematology Panel
Date: Monday, March 7, 2022
Time: 12:50 PM ET
Panel Webcast Link

Conference: 32nd Annual Oppenheimer Healthcare Conference
Format: Fireside Chat
Date: Tuesday, March 15, 2022
Time: 4:00 PM ET
Fireside Chat Webcast Link

A live webcast of the panel and fireside chat from the conferences will be available on the investors section of the X4 Pharmaceuticals’ website at www.x4pharma.com. After the live webcasts, the events will remain archived on the X4 Pharmaceuticals’ website for approximately 90 days.

About X4 Pharmaceuticals
X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company leading the discovery and development of novel therapies for people with immune system dysfunction. The company’s lead candidate is mavorixafor, a first-in-class, small molecule antagonist of chemokine receptor CXCR4 that is being developed as a once-daily oral therapy. Due to mavorixafor’s ability to antagonize CXCR4 and improve the healthy maturation and trafficking of white blood cells, X4 believes that mavorixafor has the potential to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies (PIDs) and certain types of cancer. Mavorixafor has already demonstrated clinical potential in a Phase 2 trial in people with WHIM syndrome, a rare PID. Its efficacy and safety continue to be evaluated in a global Phase 3 clinical trial in WHIM (fully enrolled) and in two Phase 1b clinical trials – one, as monotherapy in people with Severe Congenital Neutropenia (SCN) and other chronic neutropenia conditions, and another in combination with ibrutinib in people with Waldenström’s macroglobulinemia, a rare B-cell lymphoma. X4 is continuing to leverage its insights into CXCR4 biology at its corporate headquarters in Boston, Massachusetts and at its research facility in Vienna, Austria, to discover and develop additional product candidates. For more information, please visit www.x4pharma.com.


Glenn Schulman, PharmD, MPH (corporate)
VP, Investor Relations & Corporate Communications
(203) 494-7411

Daniel Ferry (investors)
Managing Director, LifeSci Advisors
(617) 430-7576

Mónica Rouco Molina (media)
Senior Account Executive, LifeSci Communications